Esperion Therapeutics | ESPR - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.22B 329M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Cipla INR 26.32B 2.79B 2026-03
CSL USD 3.87B 2.08B 2025-12
Cytokinetics USD 160K 104.24M 2026-03
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Geron USD 1.69M 386K 2026-03
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
Merck USD 2.94B 380M 2026-03
Minerva Neurosciences 386K 31K 2024-06
Moderna USD 955M 503M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 4.59B 1.7B 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sanofi EUR 3.67B 621M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12